Back to Search
Start Over
Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
- Source :
-
Journal of infection in developing countries [J Infect Dev Ctries] 2018 Sep 30; Vol. 12 (9), pp. 799-805. Date of Electronic Publication: 2018 Sep 30. - Publication Year :
- 2018
-
Abstract
- Introduction: Invasive fungal infection (IFI) is a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. A previous history of IFI is not an absolute contraindication for allo-HSCT, particularly in the era of secondary antifungal prophylaxis (SAP). Prompt diagnosis and therapy are essential for HSCT outcome.<br />Methodology: The charts of 58 allo-HSCT recipients [median age:29.5 (16-62); M/F:41/17] who had a previous history of IFI were retrospectively reviewed.<br />Results: Possible IFI was demonstrated in 32 (55.2%), probable in 13 (22.4%) and proven in 13 patients (22.4%). All patients received SAP [liposomal amphoterisin B (n ꞊ 35), voriconazole (n ꞊ 17), caspofungin (n ꞊ 2), posaconazole (n ꞊ 1), combination therapy (n = 3)] which was started on the first day of the conditioning regimen. Treatment success was better in the voriconazole group when compared to the amphotericin B arm (100% vs 69.2%; p = 0.029). Development of breakthrough IFI was more frequent in patients on amphotericin B prophylaxis (42.4% vs 23.1%; p = 0.036). Clinical and radiological response were achieved in 13 of 18 patients (72.2%) who developed breakthrough infection. Overall survival of the study population was 13.5% at a median follow-up of 154 (7-3285) days. Fungal mortality was found to be 23%. Overall survival was better in the voriconazole arm, without statistical significance (90% vs 65.8%, p > 0.05).<br />Conclusions: Secondary antifungal prophylaxis is considered to be an indispensible strategy in patients with pre-HSCT IFI history. Voriconazole seems to be a relatively better alternative despite an underlying necessity of larger prospective trials.<br />Competing Interests: No Conflict of Interest is declared<br /> (Copyright (c) 2018 mehmet sezgin pepeler, seyma yildiz, zeynep arzu yeğin, zubeyde nur ozkurt, ozlem guzel tunccan, gonca erbas, nurdan kokturk, ayse kalkanci, zeki yildirim.)
- Subjects :
- Adolescent
Adult
Allografts
Amphotericin B therapeutic use
Antibiotic Prophylaxis methods
Caspofungin therapeutic use
Drug Therapy, Combination
Female
Hematopoietic Stem Cell Transplantation mortality
Humans
Invasive Fungal Infections etiology
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Triazoles therapeutic use
Voriconazole therapeutic use
Young Adult
Antifungal Agents therapeutic use
Hematopoietic Stem Cell Transplantation adverse effects
Invasive Fungal Infections prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1972-2680
- Volume :
- 12
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Journal of infection in developing countries
- Publication Type :
- Academic Journal
- Accession number :
- 31999640
- Full Text :
- https://doi.org/10.3855/jidc.9961